Titre :

Trends in the delivery of reimbursed nicotine replacement therapies between 2016 and 2019 in France.

Auteur(s) :

Rochoy, Michaël [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Babol, A. [Auteur]
Université Lille Nord (France)
Péan, C. [Auteur]
Deleplanque, D. [Auteur]
Université de Lille
GAUTIER, Sophie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Berkhout, Christophe [Auteur]
University of Antwerp [UA]

Titre de la revue :

Therapies

Nom court de la revue :

Therapies

Numéro :

77

Pagination :

561-570

Éditeur :

Elsevier

Date de publication :

2022-02-12

ISSN :

1958-5578

Mot(s)-clé(s) :

Insurance
Health
Reimbursement
Tobacco use cessation devices

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives Describe the evolution of the expenses and the number of boxes of nicotine replacement therapy reimbursed by the French health insurance between 2016 (flat rate of €.150/year with advance payment) and 2019 (65% ...
Lire la suite >Objectives Describe the evolution of the expenses and the number of boxes of nicotine replacement therapy reimbursed by the French health insurance between 2016 (flat rate of €.150/year with advance payment) and 2019 (65% reimbursement without in advance payment and without a spending limit). Setting and participants Descriptive and analytical epidemiological study between January 1, 2016 and December 31, 2019 based on a retrospective collection of data from OpenMEDIC (the merged French health insurances drug claim database) on the number of reimbursed NRT boxes dispensed by community pharmacies and their annual cost. Results During 4 years, 7.4 million boxes of NRT were reimbursed (total cost of 148.4 million euros): approximately 300,000 in 2016, 650,000 in 2017, 1.9 million in 2018 and 4.6 million in 2019, namely a fifteen-fold increase between 2016 and 2019 (a geometric growth ratio of 2.5 each year). This increase was slightly more pronounced among men than among women, and concerned more NRT delivered from time to time (gums, tablets): transdermal devices proportion decreased from 79.7% of reimbursed NRT in 2016 to 52.9% in 2019, with an increase in gums (8% to 13.3%) and sublingual tablets (8.4% to 15.8%) over the same period. Conclusions The evolution of NRT reimbursement comes with an increase in NRT deliveries. This suggests a real medical need rather than a short trend: therefore, this suggests a catch-up in the access to care.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Date de dépôt :

2024-01-16T01:31:15Z
2024-12-11T10:48:07Z